Several series indicated that surgical stress suppresses the immune system and that the use of cardiopulmonary bypass (CPB), cardiac arrest and ischemia contributes to this [1, 2] . The most significant contributors to immune suppression are still yet to be determined. It seems that the survival of cancer patients who undergo cardiac surgery is more closely related to the progression of the tumor than the surgical procedure [3] . The reported results show a non-statistically significant increase in the risk of cancer-specific mortality for patients who underwent CPB before any diagnosis of cancer. In addition, a non-statistically significant increase was observed in the case-fatality rate for those cancer patients who underwent CPB surgery before the cancer diagnosis, and no difference was found in cancer stage at the time of diagnosis, with no impact on the relative risk of mortality. Further research is needed to know whether the transient immunosuppression associated with CPB can promote the spread and growth of pre-existing cancer cells, emphasizing that lung cancer and skin melanoma have had the most extensive association studies. In conclusion, adverse effects of CPB on cancer prognosis are expected but have not been confirmed. This editorial was motivated by the experience of an isolated case of an emphysematous, chronic smoker patient, who presented an impressive spread of an oat cell lung tumor 20 to 30 days after myocardial revascularization.
Domingo M. Braile 1 ; Paulo Roberto B. Évora 2 should be stressed that this has been a concern throughout the world, so we must join forces in the direction of these goals. Sure enough, BJCVS is a potent weapon for this purpose.
The ORBITA trial, recently published in The Lancet journal, brought important responses concerning possible placebo effect in stable angina treated by percutaneous intervention. Considering the ORBITA study as the best-designed trial comparing conservative and interventional strategies in patients with stable angina, doctors Albuquerque and Gomes, based on the rigor of the design trial, emphasize that percutaneous coronary intervention has a powerful placebo effect and should have an impact in forthcomings guidelines of stable coronary disease.
Articles in this Issue
This issue of BJCVS presents a blind peer-reviewed selection of 16 articles that will surely please your readers:
A.Two papers concerning on congenital heart disease presents and discuss: 
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